Skip to content
FIND A HEALTH VALLEY ACTOR
SOPHiA GENETICS

SOPHiA GENETICS Announces Two Million Patient Cases Analysed

07.04.2025
Share this article

SOPHiA GENETICS, a cloud-native software company based in canton of Vaud (Switzerland) and leader in data-driven medicine, has reached a historic milestone: more than two million patients genomic profiles analysed on the AI-powered analytics Platform SOPHiA DDM™.

 

 

“When we announced one million profiles analysed in 2022, it was a landmark moment in the evolution of data-driven medicine,” said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder of SOPHiA GENETICS. “Less than three years later, we have doubled that number, an acceleration that reflects both the trust our partners place in our Platform and the increasing role of AI in transforming healthcare.”

With 800 healthcare institutions across 72 countries regularly contributing their data and expertise to SOPHiA DDM, the Platform has become one of the most comprehensive sources of real-world intelligence in precision medicine. SOPHiA DDM™ analyses thousands of new oncology and rare disease cases daily, continuously refining and improving its AI capabilities. Unlike AI models trained in controlled environments, SOPHiA GENETICS’s technology is uniquely shaped by real-world data, ensuring its insights are deeply rooted in clinical reality. Now informed by over two million patient cases, the Platform empowers providers to see what others cannot, leading to faster and more accurate treatment decisions.

“At SOPHiA GENETICS, our vision was to create a Platform that could harness genetic data to benefit patients worldwide. Reaching two million genomic profiles is a historic milestone, strengthening a Platform that now integrates hundreds of millions of data points across multiple health dimensions, driving even greater impact for precision medicine,” commented Pierre Hutter, PhD., Co-founder and former CSO of SOPHiA GENETICS.

“When we founded SOPHiA GENETICS, our vision was to leverage data to make precision medicine accessible worldwide,” added Lars Steinmetz, PhD., current Chair of the Department of Genetics at Stanford University and Co-founder of SOPHiA GENETICS. “From the beginning, we knew that scale and diversity of data would be essential to making AI truly impactful in healthcare. Today, the Platform reflects an unprecedented range of profiles, ensuring that AI-driven insights are not just powerful, but also inclusive and globally relevant.”

 

➡️ Source: SOPHiA GENETICS. Read the full press release